(September 27, 2017)

Sponsored by
Tecan Group logo



This webinar introduces you to advances in prenatal screening and to a non-invasive prenatal test (NIPT) based on a flexible and scalable Next Generation Sequencing (NGS) workflow. The analysis is performed on cell-free placental DNA from a maternal blood sample which provides pregnant women fast, reliable results that reduce the need for invasive tests and the associated stress and anxiety. This NIPT is a CE-marked in vitro diagnostic product.

Learning Objectives:

  • Screening fundamentals
  • International and regional screening policies and market demands
  • Understanding non-invasive prenatal test results - diving deeper


Stephen LittleDr Stephen Little

Chief Executive Officer

Premaitha Health plc

Dr Little is a successful serial biotechnology entrepreneur. He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. DxS pioneered the use of molecular diagnostic tests such as KRAS and EGFR mutation analysis to predict the use of novel cancer therapies. In 2009, DxS was acquired by QIAGEN and Stephen became Vice President of Personalised Healthcare, responsible for developing companion diagnostic partnerships with the pharma industry. Prior to his leading role at DxS, Stephen worked for 20 years in various senior positions in the diagnostic divisions of Astra Zeneca and ICI. He holds a PhD from Heriot-Watt University in Edinburgh.


Nicholas SmithNicholas Smith

Head Global Marketing and Portfolio Management


Nicholas Smith is Head of Global Marketing and Portfolio Management for Tecan’s Partnering Business. A key function of his team is to work closely with customers to develop new product concepts and proposals based on a thorough analysis of their specific requirements. Nicholas’ joined Tecan in 2012 from Roche Diagnostics where he worked for over 20 years in a variety of roles within marketing and business development.